Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases

By sjmartinez • December 25, 2024

Aringer M, Distler O, Hoffmann-Vold AM, Kuwana M, Prosch H, Volkmann ER. Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. RMD Open. 2024 Dec 23;10(4):e004704. doi: 10.1136/rmdopen-2024-004704. PMID: 39719300.

Tags: Autoimmune Diseases, Publications, Pulmonary fibrosis, Rheumatology, Therapeutics

Preserved muscle oxidative capacity in COPD patients with hypoxemia treated by long term O2 therapy

Adami A, Vitacca M, Casaburi R, Salvi B, Simonelli C, Rossiter HB, Paneroni M. Preserved muscle oxidative capacity in COPD patients with hypoxemia treated by[...]

Mechanomedicine

Liu Z, Chen G, Jo MS, Vogel V, Chen J, Rogers JA, Li S. Mechanomedicine. Nat Rev Bioeng. 2026 Mar;4(3):216-235. doi: 10.1038/s44222-025-00391-6. Epub 2026 Jan[...]

Lupus Erythematosus Tumidus Mimicking Erythema Nodosum: A Diagnostic Challenge

Aung T, Eblen K, Pierce J, Gates G. Lupus Erythematosus Tumidus Mimicking Erythema Nodosum: A Diagnostic Challenge. Cureus. 2026 Mar 3;18(3):e104616. doi: 10.7759/cureus.104616. PMID: 41939593;[...]